Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: A mechanism for therapeutic efficacy in multiple sclerosis

Multiple Sclerosis

Volumn 8, Issue 4, 2002, Pages 299-306

  Chabot, S ^a   Yong, F P ^a   Le, D M ^a   Metz, L M ^a   Myles, T ^a   Yong, V W ^a  

^a Neuroscience Research Group   (Canada)

Author keywords

Cytokine; Lymphocyte; Microglia; Neuroinflammation; Therapeutics

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; CYTOKINE; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL INTERACTION; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MICROGLIA; MORPHOLOGY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; T LYMPHOCYTE ACTIVATION; TH2 CELL; ADULT; CELL ADHESION; CELL COMMUNICATION; COCULTURE; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; IN VITRO STUDY; MACROPHAGE; METABOLISM; T LYMPHOCYTE;

ADULT; CELL ADHESION; CELL COMMUNICATION; CELLS, CULTURED; COCULTURE; CYTOKINES; HUMAN; IMMUNOSUPPRESSIVE AGENTS; IN VITRO; MACROPHAGES; MICROGLIA; MULTIPLE SCLEROSIS; PEPTIDES; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; COCULTURE TECHNIQUES; HUMANS;

EID: 0035996211     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458502ms810oa     Document Type: Article

References (45)

1. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
2. Copolymer 1 reduces relapse rate and improves disability in relasping-remitting multiple sclerosis: Results of a phase III multicenter double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group
3. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
4. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
5. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease
6. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses
7. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1
8. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
9. Glatiramer acetate in the treatment of multiple sclerosis
10. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein
11. Copolymer-1-induced inhibition of antigen-specific T cell activation: Interference with antigen presentation
12. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis
13. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules
14. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1
15. Glatiramer acetate (Copaxone®) induces degenerate Th2-polarized immune responses in patients with multiple sclerosis
16. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking
17. Suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis
18. Copolymer 1 induces T cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis
19. Treatment of multiple sclerosis with copolymer-1 (copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation
20. Mechanisms of action of glatiramer acetate in multiple sclerosis
21. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients
22. Mechanisms of immunomodulation by glatiramer acetate
23. Treatment of multiple sclerosis with copaxone (Cop) Elispot assay detects COP-induced interleukin-4 and interferon-γ response in blood cells
24. Microglial production TNF-α is induced by activated T lymphocytes: Involvement of VLA-4 and inhibition by inteferon β-1b
25. Mechanisms of IL-10 production in human microglia - T cell interaction
26. Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: Relevance to MS
27. CNTF protection of oligodendrocytes against natural and tumor necrosis factor α-induced death
28. Myelin basic protein content of aggregating rat brain cell cultures treated with cytokines and/or demyelinating antibody: Effects of macrophage enrichment
29. Interferton beta in the treatment of multiple sclerosis: Mechanisms of action
30. Characterization of primary human fetal dissociated central nervous system cultures with an emphasis on microglia
31. Cytokine production in T cell-microglia interaction: The PMA/IFNγ-treated U937 monocytoid cells as a model of human adult microglia
32. Human neutrophil adherence to laminin in vitro. Evidence for a distinct neutropil integrin receptor for laminin
33. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naïve T cells
34. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems, and perpectives
35. Association of interleukin-1β and interleukin-1 receptor antagonist genes with disease severity in MS
36. Detection of MHC class II antigens on macrophages and microglia but not on astrocytes and endothelia in active multiple sclerosis lesions
37. Multiple sclerosis
38. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1
39. Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction: Severe paralytic disease correlates with the presence of interleukin-2 receptor-positive cells infiltrating the central nervous system
40. Chronologic localization of myelin-reactive cells in the lesions of relapsing EAE
41. Immune surveillance in the injured nervous system: T-lymphocytes invade the axotomised mouse facial motor nucleus and aggregate around sites of neuronal degeneration
42. Central nervous system microglial cell activation and proliferation follows direct interaction with tissue-infiltrating T cells blasts
43. Microglia stimulate naïve T-cell differentiation without stimulating T-cell proliferation
44. In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena
45. Copolymer-1